Vaccine Info

Janssen Adenovirus-Based COVID-19 Vaccine

Janssen Adenovirus-Based COVID-19 Vaccine Description

As soon as the novel coronavirus (COVID-19) sequence became available, Johnson and & Johnson (J&J) research teams at Janssen Pharmaceutical, in collaboration with Beth Israel Deaconess Medical Center, part of Harvard Medical School, constructed and tested multiple vaccine candidates using the Janssen AdVac® technology.

J&J’s lead vaccine candidate for COVID-19 disease leverages Janssen's AdVac and PER.C6® technologies. These are the same technology Janssen used to develop and manufacture the Company's Ebola vaccine, Ad26.ZEBOV.

J&J expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021

Janssen Adenovirus-Based COVID-19 Vaccine Indication

Janssen's vaccine candidate will be indicated to prevent infection from SARS-CoV-2 coronavirus, which leads to COVID-19 disease in humans.

Janssen Adenovirus-Based COVID-19 Vaccine News

  • April 29, 2020 - Janssen Pharmaceutical Companies of Johnson & Johnson announced Catalent’s Biologics business unit will accelerate the availability of manufacturing capacity and prepare for large-scale commercial manufacturing at its facility in Bloomington, Indiana, of Johnson & Johnson’s lead vaccine candidate for COVID-19. The collaboration commits joint investment to accelerate the rapid scale-up of segregated manufacturing capacity over the coming months to support the dedicated production of Johnson & Johnson’s investigational vaccine candidate.
  • April 23, 2020 - Emergent BioSolutions Inc. announced an agreement whereby Emergent will deploy its contract development and manufacturing services to support the manufacturing of Johnson & Johnson’s lead vaccine candidate for COVID-19 that leverages the AdVac® and PER.C6® technologies from the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement, valued at approximately $135 million, Emergent will provide drug substance manufacturing services with its molecule-to-market CDMO offering, supported by investments from Johnson & Johnson beginning in 2020, and will reserve certain large-scale manufacturing capacity to pave the way for commercial manufacturing of Janssen’s adenovirus-based COVID-19 vaccine beginning in 2021.
  • March 30, 2020 - Johnson & Johnson has identified a lead COVID-19 vaccine candidate (with two back-ups), which will progress into the first manufacturing steps. Under an accelerated timeline, the Company is aiming to initiate a Phase 1 clinical study in September 2020, with clinical data on safety and efficacy expected to be available by the end of the year. This could allow vaccine availability for emergency use in early 2021. For comparison, the typical vaccine development process involves a number of different research stages, spanning 5 to 7 years, before a candidate is even considered for approval.

Janssen COVID-19 Vaccine Clinical Trials


05/17/2020 - 14:03